Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02896335 · ClinicalTrials.gov registry record · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
A Phase 2 study of Recurrent Brain Metastases and Progressive Brain Metastases, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 2
- Study locations
NCT02896335 is a Phase 2 study of Recurrent Brain Metastases and Progressive Brain Metastases that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 45 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT02896335, a Phase 2 study of Recurrent Brain Metastases and Progressive Brain Metastases, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying This research study is studying the efficacy and safety of the following study drugs as a possible treatment for recurrent central nervous system (CNS) metastases: * Palbociclib alone (Cohort 1) * The combination of palbociclib and pembrolizumab (Cohort 2) Pfizer and Merck, pharmaceutical companies, are supporting this research study by providing the study drugs as well as funding for research activities.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Palbociclib
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-02-02 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02896335
The ClinicalTrials.gov registry entry for NCT02896335 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Recurrent Brain Metastases appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02896335 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02896335 about?
NCT02896335 is a clinical study titled "Palbociclib and Pembrolizumab In Central Nervous System Metastases". This research study is studying This research study is studying the efficacy and safety of the following study drugs as a possible treatment for recurrent central nervous system (CNS) metastases: * Palbociclib alone (Cohort 1) * The combination of palbociclib and pembrolizumab (Cohort 2) Pfizer and...
What is the current status of trial NCT02896335?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2017-02-02. Estimated completion is 2027-09-01.
What conditions does trial NCT02896335 study?
This clinical trial studies the following conditions: Recurrent Brain Metastases, Progressive Brain Metastases, Metastatic Malignant Neoplasm to Brain.
What interventions are being tested in trial NCT02896335?
The interventions under investigation include: Pembrolizumab (DRUG), Palbociclib (DRUG).
Who is sponsoring clinical trial NCT02896335?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02896335 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Recurrent Brain Metastases
All registered trials for this condition
Progressive Brain Metastases
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.